Michael W Bonney sold $3.1M of ALNY
director at ALNYLAM PHARMACEUTICALS, INC.. 11,250 shares at an average of $277.71, traded May 15, 2025, filed May 19, 2025.
Score components
- +15RoleDirector
- +25Trade size$3.1M at market
- +10Share of holdings soldSold 40% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000072, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 15, 2025 | MOption exercise Common Stock10b5-1 | +11,250 | $131.21 | $1.5M | 28,054 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -549 | $267.14 | $147k | 27,505 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -729 | $268.56 | $196k | 26,776 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -245 | $269.79 | $66k | 26,531 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -431 | $271.68 | $117k | 26,100 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -660 | $273.16 | $180k | 25,440 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -882 | $273.75 | $241k | 24,558 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -301 | $275.63 | $83k | 24,257 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -1,263 | $277.16 | $350k | 22,994 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -1,239 | $278.01 | $344k | 21,755 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -432 | $280.03 | $121k | 21,323 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -372 | $281.10 | $105k | 20,951 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -802 | $282.03 | $226k | 20,149 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -1,728 | $282.81 | $489k | 18,421 | May 19, 2025 |
| May 15, 2025 | SOpen-market sale Common Stock10b5-1 | -1,617 | $283.83 | $459k | 16,804 | May 19, 2025 |
| May 15, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -11,250 | $0.00 | $0 | 0 | May 19, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $5.5M 12,128 shares | -36% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $12M 25,650 shares | -32% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $2.7M 5,959 shares | -23% | |
| 55Moderate | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $1.1M 2,441 shares | -9% | |
| 50Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $635k 1,405 shares | -5% | |
| 70Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $4.0M 8,924 shares | -12% | |
| 62Notable | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $1.7M 3,821 shares | -7% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8.4M 18,000 shares | -96% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $1.6M 3,474 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.